Press Release
July 10, 2020

Goodwin Advises Symprove on Sale of Majority Stake to bd-capital

The London team advised Symprove, a UK-based probiotics manufacturer, in connection with private equity firm bd-capital’s investment in the company. Following the investment, the current Symprove management, including the founder and the CEO, will remain in place.

Symprove was launched in 2010 in Farnham, Surrey, founded in the belief that maintaining a healthy gut bacteria balance can help you live a fuller life. The company stays dedicated to researching the microbiome and developing Symprove’s unique, patented, water-based delivery system that supports the gut microbiome by delivering live and active bacteria to where it’s needed most.

bd-capital is a private equity firm targeting midmarket investment opportunities in healthcare, services and consumer sectors where changing patterns of consumer behaviour and technology disruption are creating growth opportunities. Founded in 2019, the Symprove partnership represents the sponsor’s first investment.

The Goodwin team was led by Graham Defries and Andrew Harrow and included Kenny Walker-Durrant, Michael Grainger and Rachel Thurbon (Life Sciences) and Carl Bradshaw, Simon Fulbrook, Samantha Lamontagne and Lisa Pearson (Private Equity), Martin Smith and Simon Woodcock (Real Estate Industry) and Rob Young (Tax).

For additional details, please read the press release.